PharmaShots | Incisive News in 3 Shots

Subscribe Now

Alnylam

PharmaShots Weekly Snapshots (September 04–08, 2023)

PharmaShots Weekly Snapshots (September 04–08, 2023)

September 9, 2023

Alnylam Reports P-II Study (KARDIA-1) Results of Zilebesiran for Hypertension in Patients at High Cardiovascular Risk

Alnylam Reports P-II Study (KARDIA-1) Results of Zilebesiran for Hypertension in Patients at High Cardiovascular Risk

September 7, 2023

Alnylam Collaborated with Roche to Co-Develop and Co-Commercialize Zilebesiran for Hypertension in Patients with High Cardiovascular Risk

Alnylam Collaborated with Roche to Co-Develop and Co-Commercialize Zilebesiran for Hypertension in Patients with High Cardiovascul...

July 24, 2023

Alnylam Reports Updated Interim Results from the P-I Study of ALN-APP for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

Alnylam Reports Updated Interim Results from the P-I Study of ALN-APP for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

July 17, 2023

Alnylam Presents 18-Month P-III Study (APOLLO-B) Results of Patisiran for ATTR Amyloidosis with Cardiomyopathy at HFA 2023

Alnylam Presents 18-Month P-III Study (APOLLO-B) Results of Patisiran for ATTR Amyloidosis with Cardiomyopathy at HFA 2023

May 22, 2023

Alnylam Expands its Collaboration with Medison Pharma to Commercialize RNAi Therapies

Alnylam Expands its Collaboration with Medison Pharma to Commercialize RNAi Therapies

March 10, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us